{"Dostarlimab": [0], "is": [1], "an": [2], "immune-checkpoint": [3], "inhibitor": [4], "that": [5, 281], "targets": [6], "the": [7, 24, 71, 120, 140, 157, 176, 187, 204, 220, 231, 291, 294, 302, 323, 328, 351], "programmed": [8], "cell": [9], "death": [10], "1": [11], "receptor.": [12], "The": [13, 110, 276], "combination": [14], "of": [15, 26, 87, 290, 299], "chemotherapy": [16], "and": [17, 80, 133, 179, 223, 257, 297, 307, 309, 312, 315], "immunotherapy": [18], "may": [19], "have": [20], "synergistic": [21], "effects": [22], "in": [23, 55, 127, 175, 186, 219, 230, 293, 301, 322, 327, 350], "treatment": [25, 286], "endometrial": [27, 50, 344], "cancer.We": [28], "conducted": [29], "a": [30, 56, 347], "phase": [31], "3,": [32], "global,": [33], "double-blind,": [34], "randomized,": [35], "placebo-controlled": [36], "trial.": [37], "Eligible": [38], "patients": [39, 142, 292, 338], "with": [40, 255, 264, 339, 346], "primary": [41, 111, 340], "advanced": [42, 341], "stage": [43], "III": [44], "or": [45, 47, 65, 100, 194, 283, 342], "IV": [46], "first": [48], "recurrent": [49, 343], "cancer": [51], "were": [52, 114, 287, 319], "randomly": [53], "assigned": [54], "1:1": [57], "ratio": [58, 191, 267], "to": [59, 107, 123, 173, 184, 200, 217, 228, 240, 253, 262, 274], "receive": [60], "either": [61], "dostarlimab": [62, 97, 177, 221, 256, 295, 324], "(500": [63], "mg)": [64, 99], "placebo,": [66], "plus": [67, 331], "carboplatin": [68], "(area": [69], "under": [70], "concentration-time": [72], "curve,": [73], "5": [74], "mg": [75, 83], "per": [76, 78, 84], "milliliter": [77], "minute)": [79], "paclitaxel": [81], "(175": [82], "square": [85], "meter": [86], "body-surface": [88], "area),": [89], "every": [90, 102], "3": [91, 108], "weeks": [92, 104], "(six": [93], "cycles),": [94], "followed": [95], "by": [96, 119, 355], "(1000": [98], "placebo": [101, 188, 232, 265, 303, 329], "6": [103], "for": [105, 192, 268], "up": [106], "years.": [109], "end": [112], "points": [113], "progression-free": [115, 161, 207, 335], "survival": [116, 162, 208, 244, 336], "as": [117], "assessed": [118], "investigator": [121], "according": [122], "Response": [124], "Evaluation": [125], "Criteria": [126], "Solid": [128], "Tumors": [129], "(RECIST),": [130], "version": [131], "1.1,": [132], "overall": [134, 205], "survival.": [135], "Safety": [136], "was": [137, 166, 212, 248], "also": [138], "assessed.Of": [139], "494": [141], "who": [143], "underwent": [144], "randomization,": [145], "118": [146], "(23.9%)": [147], "had": [148], "mismatch": [149], "repair-deficient": [150], "(dMMR),": [151], "microsatellite": [152], "instability-high": [153], "(MSI-H)": [154], "tumors.": [155], "In": [156, 203], "dMMR-MSI-H": [158, 352], "population,": [159, 206], "estimated": [160], "at": [163, 209, 245], "24": [164, 210, 246], "months": [165, 211, 247], "61.4%": [167], "(95%": [168, 181, 214, 225, 250, 259], "confidence": [169], "interval": [170], "[CI],": [171], "46.3": [172], "73.4)": [174], "group": [178, 189, 222, 233, 296, 325], "15.7%": [180], "CI,": [182, 198, 215, 226, 238, 251, 260, 272], "7.2": [183], "27.0)": [185], "(hazard": [190, 234, 266], "progression": [193], "death,": [195, 269], "0.28;": [196], "95%": [197, 237, 271], "0.16": [199], "0.50;": [201], "P<0.001).": [202, 242], "36.1%": [213], "29.3": [216], "42.9)": [218], "18.1%": [224], "13.0": [227], "23.9)": [229], "ratio,": [235], "0.64;": [236, 270], "0.51": [239], "0.80;": [241], "Overall": [243], "71.3%": [249], "64.5": [252], "77.1)": [254], "56.0%": [258], "48.9": [261], "62.5)": [263], "0.46": [273], "0.87).": [275], "most": [277], "common": [278], "adverse": [279, 317], "events": [280, 318], "occurred": [282], "worsened": [284], "during": [285], "nausea": [288], "(53.9%": [289], "45.9%": [298], "those": [300], "group),": [304], "alopecia": [305], "(53.5%": [306], "50.0%),": [308], "fatigue": [310], "(51.9%": [311], "54.5%).": [313], "Severe": [314], "serious": [316], "more": [320], "frequent": [321], "than": [326], "group.Dostarlimab": [330], "carboplatin-paclitaxel": [332], "significantly": [333], "increased": [334], "among": [337], "cancer,": [345], "substantial": [348], "benefit": [349], "population.": [353], "(Funded": [354], "GSK;": [356], "RUBY": [357], "ClinicalTrials.gov": [358], "number,": [359], "NCT03981796.).": [360]}